Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cardiomyopathies

The fatty hearts of patients with diabetes

Nature Reviews Cardiology volume 6, pages 268–269 (2009)Cite this article

Magnetic Resonance Spectroscopy is a novel research tool used to noninvasively quantify myocardial triglyceride content. This method provides the opportunity to study myocardial steatosis in patients with diabetes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Aneja, A., Tang, W. H., Bansilal, S., Garcia, M. J. & Farkouh, M. E. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am. J.Med. 121, 748–757 (2008).

    Article  Google Scholar 

  2. Szczepaniak, L. S., Victor, R. G., Orci, L. & Unger, R. H. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ. Res. 101, 759–767 (2007).

    Article  CAS  Google Scholar 

  3. Sharma, S. et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 18, 1692–1700 (2004).

    Article  CAS  Google Scholar 

  4. Rijzewijk, L. J. et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 52, 1793–1799 (2008).

    Article  Google Scholar 

  5. Schick, F. et al. Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. Magn. Reson. Med. 29, 158–167 (1993).

    Article  CAS  Google Scholar 

  6. van der Meer, R. W. et al. Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology 245, 251–257 (2007).

    Article  Google Scholar 

  7. Szczepaniak, L. S. et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn. Reson. Med. 49, 417–423 (2003).

    Article  CAS  Google Scholar 

  8. McGavock, J. M. et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 116, 1170–1175 (2007).

    Article  Google Scholar 

  9. Lindsey, J. B. & Marso, S. P. Steatosis and diastolic dysfunction: the skinny on myocardial fat. J. Am. Coll. Cardiol. 52, 1800–1802 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UT Southwestern Medical Center, Dallas, TX, USA

    Ildiko Lingvay, Philip Raskin & Lidia S. Szczepaniak

Authors
  1. Ildiko Lingvay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip Raskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lidia S. Szczepaniak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ildiko Lingvay.

Ethics declarations

Competing interests

P Raskin has received research support from Amylin Pharmaceuticals, Bayhill Therapeutics, Biodel, Inc., Boehringer Ingelheim Pharmaceuticals, Elixer Pharmaceuticals, Generex Biotechnology, Hoffmann-La Roche, Johnson & Johnson Pharmaceutical Research & Development, Keryx Biopharmaceuticals, MannKind Corporation, Novo Nordisk, Inc., Osiris Therapeutics, Inc., Pfizer, Sanofi Aventis, and Tolerx. He is an Advisor for AstraZeneca, MannKind Corporation, Novo Nordisk, Inc., and Quigley Pharma, Inc., and is on the speakers bureau for Merck & Co., and Novo Nordisk, Inc. The other authors declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lingvay, I., Raskin, P. & Szczepaniak, L. The fatty hearts of patients with diabetes. Nat Rev Cardiol 6, 268–269 (2009). https://doi.org/10.1038/nrcardio.2009.30

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2009.30

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing